



DEPARTMENT OF HEALTH & HUMAN SERVICES

*Official  
Examiner*

Food and Drug Administration  
Rockville MD 20857

Re: Omacor  
Docket Nos.: 2005E-0258,  
2005E-0247, and 2005-2033

The Honorable Jon Dudas  
Under Secretary of Commerce for Intellectual Property and  
Director of the United States Patent and Trademark Office  
Box Pat. Ext.  
P.O. Box 1450  
Alexandria, VA 22313-1450

JAN - 6 2006

Dear Director Dudas:

This is in regard to the applications for patent term extension for U.S. Patent Nos. 5,656,667, 5,698,594, and 5,502,077 filed by Pronova Biocare AS, under 35 U.S.C. section 156 et seq. We have reviewed the dates contained in the applications and have determined the regulatory review period for Omacor, the human drug product claimed by the patents.

The total length of the regulatory review period for Omacor is 3,712 days. Of this time, 3,408 days occurred during the testing phase and 304 days occurred during the approval phase. These periods of time were derived from the following dates:

1. The date an exemption under subsection 505(i) of the Federal Food, Drug, and Cosmetic Act involving this drug product became effective: September 14, 1994.

The applicant claims August 15, 1994, as the date the investigational new drug application (IND) became effective. However, FDA records indicate that the IND effective date was September 14, 1994, which was thirty days after FDA receipt of the IND.

2. The date the application was initially submitted with respect to the human drug product under section 505 of the Federal Food, Drug, and Cosmetic Act: January 12, 2004.

FDA has verified the applicant's claim that the new drug application (NDA) for Omacor (NDA 21-654) was initially submitted on January 12, 2004.


3. The date the application was approved: November 10, 2004.

FDA has verified the applicant's claim that NDA 21-654 was approved on November 10, 2004.

This determination of the regulatory review period by FDA does not take into account the effective date of the patent, nor does it exclude one-half of the testing phase as required by 35 U.S.C. section 156(c)(2).

Please let me know if we can be of further assistance.

Sincerely yours,



Jane A. Axelrad  
Associate Director for Policy  
Center for Drug Evaluation and Research

cc: Teresa Stanek Rea  
Burns, Doane, Swecker, & Mathis, LLP  
PO Box 1404  
Alexandria, VA 22313-1404